中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2015年
16期
28-29,30
,共3页
呼出气一氧化氮(FeNO)%支气管哮喘%参考指标
呼齣氣一氧化氮(FeNO)%支氣管哮喘%參攷指標
호출기일양화담(FeNO)%지기관효천%삼고지표
Fractional exhaled nitric oxide (FeNO)%Bronchial asthma%Reference index
目的：评估呼出气一氧化氮（fractional exhaled nitric oxide，FeNO）在支气管哮喘诊治中的意义。方法选取未规范使用控制药物的哮喘患者30例，给予为期4周的布地奈德福莫特罗（信必可都保160/4.5μg，每天2次）吸入治疗，检测治疗前后的FeNO水平、肺功能、ACT评分。同期选取30例健康受试者，给予检测FeNO及肺功能水平。结果哮喘组患者吸入信必可治疗后的FeNO水平（体积分数）较治疗前显著降低（35.23±15.61 vs 66.81±38.57，P＜0.05）。治疗前的FeNO水平明显高于健康对照组（66.81±38.57 vs 18.62±11.30，P＜0.05），治疗后的FeNO水平也明显高于健康对照组（35.23±15.61 vs 18.62±11.30，P＜0.05）。治疗后的FEV1/pred较治疗前显著改善（83.45±14.56 vs 71.19±16.52，P＜0.05）；治疗后的ACT评分显著高于治疗前（22.46±2.06 vs 15.26±4.35，P＜0.05）；治疗前的FEV1/pred水平与ACT评分呈直线正相关（r=0.492，P＜0.01），FeNO与FEV1/pred及ACT评分无直线相关关系。结论 FeNO水平是一种评估气道炎症程度的参考指标，与肺功能及患者临床症状结合可以从不同的层面结合更好地反应哮喘的疾病控制程度。
目的：評估呼齣氣一氧化氮（fractional exhaled nitric oxide，FeNO）在支氣管哮喘診治中的意義。方法選取未規範使用控製藥物的哮喘患者30例，給予為期4週的佈地奈德福莫特囉（信必可都保160/4.5μg，每天2次）吸入治療，檢測治療前後的FeNO水平、肺功能、ACT評分。同期選取30例健康受試者，給予檢測FeNO及肺功能水平。結果哮喘組患者吸入信必可治療後的FeNO水平（體積分數）較治療前顯著降低（35.23±15.61 vs 66.81±38.57，P＜0.05）。治療前的FeNO水平明顯高于健康對照組（66.81±38.57 vs 18.62±11.30，P＜0.05），治療後的FeNO水平也明顯高于健康對照組（35.23±15.61 vs 18.62±11.30，P＜0.05）。治療後的FEV1/pred較治療前顯著改善（83.45±14.56 vs 71.19±16.52，P＜0.05）；治療後的ACT評分顯著高于治療前（22.46±2.06 vs 15.26±4.35，P＜0.05）；治療前的FEV1/pred水平與ACT評分呈直線正相關（r=0.492，P＜0.01），FeNO與FEV1/pred及ACT評分無直線相關關繫。結論 FeNO水平是一種評估氣道炎癥程度的參攷指標，與肺功能及患者臨床癥狀結閤可以從不同的層麵結閤更好地反應哮喘的疾病控製程度。
목적：평고호출기일양화담（fractional exhaled nitric oxide，FeNO）재지기관효천진치중적의의。방법선취미규범사용공제약물적효천환자30례，급여위기4주적포지내덕복막특라（신필가도보160/4.5μg，매천2차）흡입치료，검측치료전후적FeNO수평、폐공능、ACT평분。동기선취30례건강수시자，급여검측FeNO급폐공능수평。결과효천조환자흡입신필가치료후적FeNO수평（체적분수）교치료전현저강저（35.23±15.61 vs 66.81±38.57，P＜0.05）。치료전적FeNO수평명현고우건강대조조（66.81±38.57 vs 18.62±11.30，P＜0.05），치료후적FeNO수평야명현고우건강대조조（35.23±15.61 vs 18.62±11.30，P＜0.05）。치료후적FEV1/pred교치료전현저개선（83.45±14.56 vs 71.19±16.52，P＜0.05）；치료후적ACT평분현저고우치료전（22.46±2.06 vs 15.26±4.35，P＜0.05）；치료전적FEV1/pred수평여ACT평분정직선정상관（r=0.492，P＜0.01），FeNO여FEV1/pred급ACT평분무직선상관관계。결론 FeNO수평시일충평고기도염증정도적삼고지표，여폐공능급환자림상증상결합가이종불동적층면결합경호지반응효천적질병공제정도。
Objective To evaluate the signiifcance of fractional exhaled nitric oxide(FeNO) in the diagnosis and treatment of bronchial asthma. Methods Thirty asthmatic patients without standard medication treatment were recruited.Budesonide Fomoterol(160/4.5μg, bid)was used for four weeks to evaluate the changes of FeNO Level, pulmonary functions and ACT scores. At the same time, thirty healthy people were recruited as control group and their FeNO levels and pulmonary functions were tested. Results After treated with Budesonide Fomoterol, the FeNO levels(volume fraction) of asthmatic patient were signiifcantly lower than those before treatment(35.23±15.61 vs 66.81±38.57,P<0.05). Meanwhile, the FeNO levels of asthmatic patients were markedly higher than those of controllers before treatment (66.81±38.57 vs 18.62±11.30,P<0.05), and after treated(35.23±15.61 vs 18.62±11.30,P<0.05). After treatment with Budesonide Fomoterol, the FEV1/pred levels(83.45±14.56 vs 71.19±16.52, P<0.05), the ACT scores(22.46±2.06 vs 15.26±4.35, P<0.05)of asthmatic patients were signiifcantly higher than their pre-treatment levels, FEV1/pred levels before treatment and ACT scores show linear positive correlation in asthmatic patients(r=0.492, P<0.01), while, the FeNO levels have no linear correlation with FEV1/pred levels and ACT scores. Conclusions FeNO level may be a good parameter for the degree of eosinophlic airway inlfammation. Combined with pulmonary function and clinical symptoms in patients with asthma can be combined with better response from different aspects of the degree of disease control.
